Gilead continues its divergence out of its original infectious disease beginnings and into cancer and now, more deeply than ...
Can the upcoming J.P. Morgan Healthcare Conference next week trigger a flurry of biotech M&A deal making activity. Read more ...
Monte Rosa Therapeutics (GLUE) outlined anticipated 2025 milestones ahead of its participation in the 43rd Annual J.P. Morgan ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback